Vamorolone Patent Expiration
Vamorolone is Used for treating Duchenne Muscular Dystrophy. It was first introduced by Catalyst Pharmaceuticals Inc
Vamorolone Patents
Given below is the list of patents protecting Vamorolone, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Agamree | US11382922 | Aqueous oral pharmaceutical suspension compositions | Jul 16, 2040 | Catalyst Pharms |
| Agamree | US11471471 | Aqueous oral pharmaceutical suspension compositions | Mar 17, 2040 | Catalyst Pharms |
| Agamree | US12201639 | Aqueous oral pharmaceutical suspension compositions | Mar 17, 2040 | Catalyst Pharms |
| Agamree | US11690853 | Non-hormonal steroid modulators of NF-κβ for treatment of disease | Mar 07, 2033 | Catalyst Pharms |
| Agamree | US10857161 | Non-hormonal steroid modulators of NF-kB for treatment of disease | May 28, 2029 | Catalyst Pharms |
| Agamree | US11833159 | Non-hormonal steroid modulators of NF-kB for treatment of disease | May 28, 2029 | Catalyst Pharms |
| Agamree | US8334279 | Non-hormonal steroid modulators of NF-κB for treatment of disease | May 28, 2029 | Catalyst Pharms |
Vamorolone's Family Patents
Explore Our Curated Drug Screens
Clinical Trials
Recent Clinical Trials on Vamorolone:
Sometimes companies keep conducting clinical trials even after the drug's approval to discover new formulations, methods of use, or new treatment indications, so they could file for additional patents or receive regulatory exclusivity extensions, such as pediatric exclusivity, potentially delaying generic competition. Based on these recent clinical trials, generic companies need to consider the potential for new intellectual property or regulatory hurdles. These strategic moves by the drug owner might delay generic substitution or lead to additional sales of the brand drug, even after patent expiry.
| Title | Lead Sponsor | Collaborators | Status | Phases |
|---|---|---|---|---|
 | ||||
| A Study to Assess Vamorolone in Becker Muscular Dystrophy (BMD) | ReveraGen BioPharma, Inc. | NA |
COMPLETED
(Sep 1, 2026)
| PHASE2 |